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Abstract
Elite suppressors (ES) are a rare population of HIV-infected individuals that are capable of naturally controlling the infection
without the use of highly active anti-retroviral therapy (HAART). Patients on HAART often achieve viral control to similar
(undetectable) levels. Accurate and sensitive methods to measure viral burden are needed to elucidate important
differences between these two patient populations in order to better understand their mechanisms of control. Viral burden
quantification in ES patients has been limited to measurements of total DNA in PBMC, and estimates of Infectious Units per
Million cells (IUPM). There appears to be no significant difference in the level of total HIV DNA between cells from ES
patients and patients on HAART. However, recovering infectious virus from ES patient samples is much more difficult,
suggesting their reservoir size should be much smaller than that in patients on HAART. Here we find that there is a
significant difference in the level of integrated HIV DNA in ES patients compared to patients on HAART, providing an
explanation for the previous results. When comparing the level of total to integrated HIV DNA in these samples we find ES
patients have large excesses of unintegrated HIV DNA. To determine the composition of unintegrated HIV DNA in these
samples, we measured circular 2-LTR HIV DNA forms and found ES patients frequently have high levels of 2-LTR circles in
PBMC. We further show that these high levels of 2-LTR circles are not the result of inefficient integration in ES cells, since HIV
integrates with similar efficiency in ES and normal donor cells. Our findings suggest that measuring integration provides a
better surrogate of viral burden than total HIV DNA in ES patients. Moreover, they add significantly to our understanding of
the mechanisms that allow viral control and reservoir maintenance in this unique patient population.
Citation: Graf EH, Mexas AM, Yu JJ, Shaheen F, Liszewski MK, et al. (2011) Elite Suppressors Harbor Low Levels of Integrated HIV DNA and High Levels of 2-LTR
Circular HIV DNA Compared to HIV+ Patients On and Off HAART. PLoS Pathog 7(2): e1001300. doi:10.1371/journal.ppat.1001300
Editor: Michael Emerman, Fred Hutchinson Cancer Research Center, United States of America
Received August 20, 2010; Accepted January 19, 2011; Published February 24, 2011
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public
domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: This work was supported by NIH grants 5K02AI078766-03 and 1R21AI087461-01. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: unao@mail.med.upenn.edu
. These authors contributed equally to this work.
Introduction
A small percentage (less than 0.5%) of people who are infected
with Human Immunodeficiency Virus (HIV) are capable of
naturally controlling the infection without the use of highly active
anti-retroviral therapy (HAART) [1–7]. These patients, termed
elite suppressors (ES), are seropositive but maintain viral RNA
levels in plasma below 50–75 copies per mL [1]. The mechanisms
involved in viral control may include a combination of viral [8,9]
and host-mediated factors [10–12], which appear to be variable
between patients [2,4]. This group, therefore, is likely comprised of
a heterogeneous population of people controlling virus replication
by different mechanisms [3,13] and to different extents [14].
Accurate and sensitive methods to measure very low viral burden
by different parameters are needed to further characterize this
patient population and may help identify subsets within this
category.
Viral burden in HIV infected patients can be measured as viral
particles containing RNA, cell associated viral RNA, and total and
integrated viral DNA. Viral burden quantification in ES has been
limited to measurements of viral RNA in plasma, cell-associated
viral RNA or total DNA (often described as ‘‘proviral DNA’’) in
PBMC, and estimates of Infectious Units per Million cells (IUPM)
[14–17]. To our knowledge, there have been no previous attempts
to specifically measure integrated DNA in ES patients. Integrated
viral DNA is believed to be of great importance in the
establishment of a latent reservoir that is resistant to HAART
and measuring integration may serve as a surrogate measure of the
viral reservoir in the absence of ongoing replication [18]. The
establishment of this latent reservoir is thought to occur early in
the course of infection [19], but the contribution of integrated HIV
DNA to viral persistence in ES patients remains unknown. Here,
we apply a unique, sensitive and precise method to measure
integrated HIV DNA in PBMC samples obtained from ES
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integration in this cohort, we increased the sensitivity of our
previously described repetitive sampling Alu-gag PCR integration
assay [20] by increasing the number of genomes assayed per well.
We find low but measurable levels of integrated DNA in 10 out of
10 ES patients with a wide distribution of levels of integration
between patients. The level of integration in ES patients was
significantly lower than that in equally suppressed patients on
HAART. This is intriguing, given that we and others [17] find the
level of total HIV DNA in ES patients is similar to that in HAART
treated patients, albeit with small data sets for comparison. To
determine if the unintegrated HIV DNA in the ES samples was
due to the accumulation of 2-LTR circular DNA, we measured 2-
LTR circular HIV DNA in these (and other) samples. We found 2-
LTR circles were present at detectable levels more often in
samples from ES patients, compared to samples from patients on
HAART and off HAART. Furthermore, the levels of 2-LTR
circular HIV DNA were higher in ES than in on-HAART
patients. As shown through in vitro inoculations, the excess of 2-
LTR circles was not due to an innate restriction at the level of
integration in the ES cells since integration occurred with similar
efficiency in CD4+ T cells from ES and normal donors after in vitro
inoculation with HIV.
Results
Generation and validation of our quantitation methods
for HIV Integration (Figure 1)
As previously described, a linear correlation exists between the
average natural log of the Alu-gag cycle thresholds (Cts), and the
natural log of the number of integrated HIV DNA copies per well
(Figure 1A). Using these methods we can detect down to 1 copy of
HIV DNA integrated in 15,000 genomes (7,500 diploid cells). To
enhance the sensitivity of our assay in order to measure lower
integration levels, we simply added more genomes to each well
and created a new standard curve for samples of DNA at 300,000
genomes per 50 ml reaction (Figure 1B). We needed to generate a
Figure 1. Linear correlation between Ln (Ct of Alu-gag) and Ln (HIV DNA copies per well) at low and high DNA concentrations. The
integration standard was diluted in PBMC DNA from HIV-negative donors at 2 (A)o r4 0( B) mg/ml as indicated for each standard curve in order to
obtain samples containing known numbers of integrated HIV DNA copies. 25 ml of the standard were then assayed per well after adding 25 ml of the
PCR master mixture for a total of 50 ml in each reaction. The final concentration of HIV DNA in each well is therefore, 1 and 20 mg/ml for the low and
high DNA concentrations, respectively. Each point represents the average Ln(Ct) for 42 replicates.
doi:10.1371/journal.ppat.1001300.g001
Author Summary
Although HIV infection usually results in a syndrome of
immunodeficiency, there is a small group of people
infected with the virus who naturally control the infection.
These subjects (called elite suppressors) are capable of
mounting a more effective immune response against the
virus, which maintains virus levels below detectable limits
without clearing the infection. When plasma virus levels
are this low, however, it becomes difficult to determine
how much virus is present, and whether there are changes
in viral burden over time. Here we show that measuring
the level of integrated HIV DNA in this patient population
provides valuable information regarding the mechanisms
involved in viral control. Specifically, we show that levels of
integrated HIV DNA are much lower in elite suppressors
compared to other patients on and off anti-retroviral
drugs, consistent with having a smaller reservoir. We show
that 2-LTR circles, comprised of DNA that is replication
incompetent, are much more common in elite suppres-
sors. Thus, we identified two important differences
between elite suppressors and other HIV infected individ-
uals. We further show that ES cells appear to be just as
susceptible to HIV integration as those from uninfected
donors, suggesting that the elevated 2-LTR circles are not
the result of an inherent restriction to integration. We
conclude that measuring integration of HIV DNA in patient
samples may provide a surrogate measure of viral burden
in these and other patients with HIV.
HIV DNA Integration in Elite Suppressors
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expected, Alu-gag signal per integration level is weaker at higher
genome copies. This is expected because increased genomes will
result in a larger number of Alu-Alu competitive reactions. As
before, we then calculate the average level of integration and the
95% confidence interval using the standard curve and the 42
replicates as described [20]. To use this method, we require that
the average Alu-gag Ct is lower than the average gag-only Ct. At
lower levels of integration, the average Alu-gag Cts were not
statistically different than the gag-only Cts. However, we found that
individual Alu-gag Cts were clearly significantly different than the
gag-only signals. Thus, we found that we could correlate the
percent positive Alu-gag signals to the proviral number as described
in detail in Figure S1, allowing us to quantify even lower
integration values.
We validated both methods of quantitation (Alu-gag Ct values vs
percent positive signals) by demonstrating that we could achieve
similar measurements for a given sample using both standard
curves (Table S1). Additionally, we validated the reproducibility of
both methods by measuring the same sample on different days
(Table S1, samples D and E). Finally, we determined the
coefficient of variation for total and integrated DNA measure-
ments by preparing DNA from 6 separate aliquots of PBMC. Each
total and integrated HIV DNA measurement was performed on
different days by 3 different individuals (Table S2).
HIV DNA Integration levels in ES patient samples
(Figure 2)
Using the above methods designed to measure integration in
patients with extremely low levels of integrated HIV DNA, we
assayed ten elite suppressors (Table 1) at 300,000 genomes per
50 ml. Integration was measurable in all ten elite suppressor
samples tested. The median level of integration (+/2S.D.) for the
cohort was 14.4, +/216.0 integrated HIV DNA copies per million
PBMC. Integrated HIV DNA levels ranged from one copy in
19,000 cells all the way down to around one copy in 2 million cells.
For 4 of the 10 patients, it was necessary to use the percent positive
method at 300,000 genomes in 50 ml due to the low level of
integrated HIV DNA in the sample (patients 1, 5, 6 and 8) as
described in Figure S1. For the remaining 6 patients, the average
Ct method was valid.
Elite suppressors have smaller reservoirs than HAART
treated patients (Figure 2 and Figure 3)
The levels of integrated HIV DNA found in 10 elite suppressors
(Table 1) were compared to the levels in 21 HAART treated
subjects and 8 patients off HAART. Measurements from six of the
off HAART patients and ten of the on HAART patients were
previously published in Yu et al. [21] and measurements from
seven of the on HAART patients were previously reported in
Agosto et al. [22]. Table S3 reports the characteristics for the
remaining patients (4 on and 2 off HAART). All HAART treated
patients had viral loads below the limit of detection and the CD4
+
T cell counts for the cohort were not statistically different from
Figure 2. Elite suppressors have lower levels of integration than other HIV+ patients on and off HAART. HIV DNA Integration levels
from ten ES patients were compared to the levels found in 21 patients on and 8 patients off HAART. Individual levels of total and integrated HIV DNA
have been previously published for 10 of the patients on and 6 of the patients off HAART [21,22]. The level of integration in ES patients was
significantly lower than patients off and on HAART. The level in the on HAART group was also statistically lower than off HAART (p,0.001, statistical
test described in methods). The line represents the median value.
doi:10.1371/journal.ppat.1001300.g002
Table 1. Elite suppressor characteristics.
Patient
number
Viral load
(copies/mL)
Year of
diagnosis
CD4+T cell
count (cells/mL)
1 8 1985 1232
2 1.5 1985 892
3 16.3 1998 1616
4 ,1 1989 745
5 ,1 1996 997
6 1 1991 643
7 ,1 1987 655
8 ,50 1985 679
9 ,50 1997 559
10 ,50 1987 884
doi:10.1371/journal.ppat.1001300.t001
HIV DNA Integration in Elite Suppressors
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test p.0.05). Although both patient populations have undetect-
able viral loads, the level of integrated HIV DNA in elite
suppressors is significantly lower than that found in HAART
treated patients (Figure 2, p, 0.001), consistent with a smaller and
difficult to measure reservoir size (as had been previously assessed
by attempts to culture out infectious virus [15,17]). For a subset of
ES and on HAART patients we were able to normalize our data to
CD4
+ T cell counts and to mL of blood. The level of integrated
HIV DNA per CD4
+ T cell or per mL was still significantly
lower in the ES group compared to patients on HAART (Figure
S2 A,C).
Samples were also subjected to PCR targeting the RU5 region
as a measure of total HIV DNA. Intriguingly, HIV RNA/mL of
plasma [14,16] and total HIV DNA per cell [17] are similar in
these two patient populations. We confirmed this comparison
within this sample population, noting no significant difference in
the level of total HIV DNA between ES patients and patients on
HAART (Figure 3). In addition, when normalized to CD4
+ T cell
count or mL of blood, the level of total HIV DNA is still not
statistically different between patients on HAART and ES,
although the median level is lower in ES (Figure S2 B,D).
Measures of total and integrated HIV DNA in ES patients
show a large excess of unintegrated HIV DNA (Figure 4)
Previous measures of total HIV DNA in ES patients showed
similar levels in ES patients and patients on HAART [17] and our
data support this conclusion (Figure 3). A few studies suggest total
may be slightly lower in ES [2,23] thus a larger number of samples
might reveal total HIV DNA is slightly lower in ES. Here we show
in 10 ES patients there is a large difference between the levels of
total and integrated HIV DNA in the ES patient population
(Figure 4 A,B), suggesting that measuring total HIV DNA is not a
suitable estimate of the size of the HIV reservoir in ES. We also
compared the ratios of total vs. integrated HIV DNA measured in
each patient sample, as an estimate of excess unintegrated HIV
DNA, and found a significant difference between ES patients and
patients on and off-HAART (Figure 4B).
2-LTR circles in patient samples (Figure 5)
In order to determine if the excess of unintegrated HIV DNA
found in ES patients is due to the accumulation of circular DNA
intermediates we measured 2-LTRs in each patient sample. We
assayed samples from 12 of the 21 patients on HAART, 8 patients
off HAART, and 10 ES patients for 2-LTR circles using 1 million
cells per replicate in at least three wells. We detected 2-LTRs in 4/
12 (33%) of the patients on-HAART, 3/8 (37.5%) of the patients
off-HAART and 9/10 (90%) of the ES patient samples. Figure 5
shows the median and standard deviation of the 2-LTR levels for
the samples in which we detected signals in each patient
population. The median level of circular 2-LTR DNA in ES
patients is significantly higher than that in the on HAART patient
population. Our ability to detect 2-LTR HIV DNA is consistent
with previous reports in the literature [24–27] and suggests that 2-
LTR circles are a minor component in chronic progressors on and
off-HAART. However, when we assayed 2-LTR circles in the ES
samples, we detected them in 9 of the 10 patients we sampled and
the median levels were higher than those found in patients on
HAART, by Wilcoxon rank-sum test (Figure 5).
Excess of 2-LTR circles in ES are not explained by innate
restriction to integration (Figure 6 and Table 2)
To examine whether the high levels of 2-LTR circles found in
ES could be explained by a block to infection after reverse
transcription but prior to integration, ES cells were infected in vitro.
We negatively isolated unstimulated CD4
+ T cells, by bead
depletion, from all 10 ES samples, and spinoculated with an X4-
tropic virus (NL4-3) in the presence of saquinavir. As controls, cells
Figure 3. Total HIV DNA is not significantly different in patients on HAART and ES patients. Total HIV DNA was measured by RU5
quantitative PCR in PBMC from 2 non-controllers off and 4 on HAART and elite suppressor patients. Serial two-fold dilutions (from 1e6 to 2.5e5 cells
per well) were measured in triplicates for each sample. This was repeated on a separate extraction for all ES. In all cases inhibitors were demonstrated
to be absent by dose response in 3 serial two-fold dilutions. Data from 6 off and 17 on HAART patients previously measured was also included for
analysis [21,22]. Patients off HAART have higher levels of total HIV DNA than other patient populations. The level of total HIV DNA was not
significantly different between patients on HAART and ES, while both were significantly lower than patients off HAART (p=0.002 for both). The line
represents the median value.
doi:10.1371/journal.ppat.1001300.g003
HIV DNA Integration in Elite Suppressors
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cells. At two and four days post-inoculation, we isolated DNA and
measured reverse transcription and integration. The levels of
reverse transcription and integration were not statistically different
when compared with normal donors two days (Figure 6A) and four
days (data not shown) after infection. Moreover, the integration
efficiency was the same between the two populations as shown by
integrated copies per reverse transcript (Figure 6A). To ensure that
ES did not possess a restrictive factor that was oversaturated at a
high MOI, we also infected 6 of the 10 ES samples with serial
dilutions of virus, down to a 1:1,000 dilution. Consistent with the
high MOI data (Figure 6A), the dilution series also yielded similar
levels of reverse transcription, integration, and integration
efficiency (integrated copies per reverse transcript) between the
normal donor and ES cells (Figure 6B). In Table 2 we compared
the percent of HIV DNA that was integrated between the ES in
vitro experiments at a 1:1000 dilution (to mimic in vivo levels of
infection) and ES in vivo measurements. We find that ES cells
contain a lower percentage of integrated HIV DNA in vivo when
compared to the levels after in vitro inoculation (Table 2). The
lower percentage found in vivo in ES is consistent with the idea that
these cells are under stronger immune pressure. A CCR5 tropic
HIV was also tested in the same system, yielding similar results
(data not shown). These results argue against the presence of an
Figure 4. ES patients have a large excess of unintegrated HIV DNA. Total and integrated HIV DNA was compared in ES patients (A). The ratio
was then calculated by dividing the number of total HIV DNA copies per cell by the number of integrated HIV DNA copies per cell for each patient
sample, and these were compared to patients on and off HAART. The excess of unintegrated HIV DNA was significantly higher in the ES patient
population than either patients on or off HAART (B). However, the levels were not different between patients on and off HAART (p=0.172). The line
represents the median value.
doi:10.1371/journal.ppat.1001300.g004
HIV DNA Integration in Elite Suppressors
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high levels of 2-LTR circles.
Discussion
A small percentage of people that become infected with HIV-1
are able to naturally control viral levels without the use of
antiretroviral therapies. Understanding the mechanisms that
enable control of viremia in these patients could further our
understanding of the pathogenesis of this virus and aid in the
development of vaccines against HIV-1. Since this population is
defined by having undetectable virus levels in plasma (using
conventional methods of detection), other methods need to be
employed to measure differences in viral burden within this group.
Our lab has developed a very accurate and sensitive method for
quantitation of integrated HIV DNA in PBMC from patients with
HIV [20,21,28] based on Alu repeats [29,30]. Using a well-
described integration standard we enhanced our methods of
quantitation to measure very low levels of integration. We quantify
low levels of integrated viral copies by increasing the number of
genomes we assay per well. Furthermore, by counting the percent
of positive Alu-gag signals after using our repetitive sampling Alu-gag
PCR integration assay, we further lowered our limit of detection to
enable quantitation of very low numbers of integrated HIV DNA
copies in each patient sample. Using these methods we found that
ES patients harbor lower levels of integrated HIV DNA compared
to patients whose plasma viremia is equally suppressed by highly
active antiretroviral therapy (HAART). This is an important
difference between ES and patients on HAART given that viral
RNA/ml [14,16] and total DNA/cell [17] are similar in these two
groups. We also found higher levels of 2-LTR circles in ES patient
samples compared to samples from patients on HAART, which
confirms our finding of a large excess of unintegrated HIV DNA in
ES samples.
Elite suppressors and HAART treated patients are not
distinguishable when some measures of viral burden are compared
such as viral RNA in plasma and total HIV DNA copies in cells.
Independent groups have compared viral RNA/ml of plasma in
ES and patients on-HAART by these methods and found similar
levels between these populations [12,14–16,31]. More recently,
Julg et al compared total HIV DNA levels in ES and HAART
treated patients and again found no significant differences in viral
burden as assessed by total HIV DNA [17]; although though
another study found slightly lower levels of total HIV DNA but did
not do a direct comparison to patients on HAART [2].
One clear difference between ES and HAART treated patients
is the size of the reservoir as estimated by using Infectious Unit Per
Million (IUPM) assay. This method enumerates the number of
latently infected cells, or the number of cells capable of producing
infectious virus following stimulation of cells in vitro. Blankson et al
used this approach to characterize replication competent HIV-1 in
a subset of ES and was able to successfully culture 6 viral isolates
from 4 ES. In this study, virus was not cultured from 6 of the 10
participants, making viral load quantification impossible in these
patients. Nevertheless, the authors could conclude that the viral
reservoir in ES must be at least one log lower than that of HAART
treated patients using the IUPM assay. Julg et al also attempted to
recover replication competent viruses from ES and were only able
to detect replicating viruses in 2 of 14 ES sampled, even though
they found equal numbers of total HIV DNA copies in ES and
HAART treated patients [17]. In summary, viral quantitation in
this patient population using the IUPM method was only possible
in 6 out of 24 (25%) of the patients tested. Thus, viral reservoir size
is smaller in ES compared to HAART patients, but it is difficult to
measure viral reservoirs by the IUPM assay because the reservoir
size is nearing detection limits for this assay.
Taken together, these prior studies point towards an important
discrepancy between total HIV DNA/cell measures and reservoir
size. Low levels of integrated HIV DNA in ES can explain the
discrepancy between total HIV DNA and reservoir size. Total
HIV DNA is made up of integrated and unintegrated HIV DNA
forms. Unintegrated HIV DNA forms accumulate in cells when
reverse transcription is completed but integration does not occur.
2-LTR circles are noted to accumulate to high levels when
Figure 5. ES patients harbor higher levels of 2-LTR circles than HIV+ patients on HAART. DNA samples from ten ES patients were analyzed
for 2-LTR circular HIV DNA. 2-LTR circular HIV DNA levels were compared to those in samples from HIV+ patients on and off-HAART. Only ES and on
HAART could be compared due to small samples size. The level of 2-LTR circles was higher in ES as was the frequency with which they were detected
(p=0.007, chi-square test). The line represents the median value.
doi:10.1371/journal.ppat.1001300.g005
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+ T cells are not resistant to in vitro infection. CD4+ T cells from 10 ES and 6 uninfected donors were inoculated with NL4-3
(A). Reverse transcripts and integrated HIV DNA were measured at 2 days post-infection. From these values, integration efficiency was calculated (i.e.
integrated copies per reverse transcript). ES were compared to normal donors with a Wilcoxon rank-sum test. Neither reverse transcription,
integration nor integration efficiency measurements were statistically different between the two populations. Six ES were also inoculated with 3 serial
ten-fold dilutions of the same virus (B). The bars represent the averages of multiple experiments (n is indicated in figures) and the error bars represent
the standard deviations.
doi:10.1371/journal.ppat.1001300.g006
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especially circular forms which are a dead-end product) is thought
to contribute minimally, if at all, to viral production [34–41].
Thus, it stands to reason that measuring integrated HIV DNA is a
better surrogate of replication competent virus than total HIV
DNA. Nonetheless, how good a surrogate integrated DNA is for
reservoir size remains unclear.
There is data to suggest that integrated DNA may be a useful
surrogate for reservoir size. For example, studies suggest that the
reservoir size is constant over time [42,43] and that the level of
integrated HIV DNA is relatively constant over time ([44–47] and
our unpublished data). The similar kinetic profile between these
two parameters suggests they mimic each other. Here we find that
integrated HIV DNA is very low in ES consistent with studies
showing that reservoir size, as estimated by IUPM, is low in ES.
Thus, our data further support that integrated HIV DNA may be
a useful surrogate for reservoir size. Given the difficulty and cost to
measure IUPM and that IUPM cannot even be detected in some
ES, measurement of integration would be an attractive surrogate if
valid. Notably, we successfully measured integration levels in all
ES samples.
Measurements of integrated HIV DNA in ES may provide
useful information and help characterize this unique group of
patients. In one study, Hatano et al measured levels of HIV RNA
in plasma, cell-based HIV RNA, and total DNA in patients with
plasma levels ,50–75 copies/ml who had not received antiretro-
viral therapies [16]. The authors showed a trend toward a slow
increase in viral RNA levels, suggesting the reservoir size may
increase over time. In addition, viral evolution is detectable in ES
supporting the notion that ongoing replication is present in this
patient cohort [48,49]. Perhaps, by applying our methods of
detection for integrated HIV DNA over time in ES we could
detect small changes in viral reservoirs in this patient population.
In another study, Sedaghat et al studied a cohort of ES over-time
and failed to detect changes in CD4
+ T cell counts over a 10-year
period. However, they demonstrate in one patient that treatment
with HAART led to a marked decrease in markers of immune
activation [50]. Whether ES would benefit from therapeutic
intervention is currently unknown, but more sensitive measures of
changes in reservoir size over time may help us determine the
effect of therapeutic interventions in this patient subset.
Our patient data raises the possibility that T cells in ES patients
may restrict HIV before the step of integration. In other words, if
integration occurs inefficiently then more 2LTRs will form. We
found no obvious restriction to integration after in vitro
inoculation of CD4+ ES cells. These results are consistent with
studies that demonstrated the kinetics of spreading infection were
similar in activated ES and normal donor cells [17,51].
At least three possibilities exist to explain our in vivo
observations. One, ES CD4+T cells contain a restrictive factor
that limits infection. Two, the 10 ES patients possess defective
viruses that are inefficient at infection. Three, cytotoxic T
lymphocytes destroy infected cells thus lowering the level of
integrated HIV DNA, while cells containing 2-LTR circles are
preserved. We were only able to partially test the first of these
theories in the current work. We find that after inoculation in
vitro, even at very low multiplicities of infection, ES CD4+T cells
have similar integration efficiencies compared to normal donors.
Defects at other steps of life cycle may still exist within ES cells and
have only been partially addressed by the literature. Consistent
with our data, spreading infection occurs with similar efficiency in
activated PBMC from ES and normal donors; however, these cells
were artificially activated and so may not be representative of cells
in vivo [51,17]. Notably, it was recently reported at International
AIDS Symposium by Lichterfeld et al. that some steps in the viral
life cycle appear to be restricted in HIV inoculated cells from ES
patients, suggesting cellular restriction factors should not be
completely ruled out. At the same time a recent report shows ES
cells expressed similar levels of GFP after infection with an R5 or
X4 pseudotyped GFP vector [52]. Therefore, if restrictions exist
they likely involve accessory proteins that were not present in the
recent report [52]. In conclusion, our data suggests that there is
not a restriction at the step of integration. However, there are
limitations to our and others’ in vitro experiments. For example, it
remains possible that there are restrictions at other steps in the
viral life cycle. It is also possible that primary isolates would show a
restriction not apparent with NL4-3 or AD8.
The lack of a restriction to integration leads us to suspect that
CTL pressure on infected cells in ES individuals may eliminate
cells with successful integration leading to lower levels of integrated
HIV DNA. Strong CTL activity could keep the level of integration
low by targeting cells that contain integrated HIV DNA if
integration leads to the expression of HIV specific proteins that
can be processed and presented at their surface. Several studies
show CTL responses are more effective in ES than other HIV-
infected individuals [12,51,53-61]. In addition, cells that contain 2-
LTR circles should be under less CTL pressure as they express less
HIV proteins. Furthermore, they may accumulate to higher levels
because ongoing replication persists in ES [48,49]. To understand
the accumulation of 2-LTR circles in ES it may be important to
determine the half-life of T cell subsets in ES patients given the low
level of activation compared to progressors [62] and possibly
patients on HAART [63].
In conclusion, we developed and validated a method of
quantitation that is accurate and sensitive enough to measure
very low levels of integrated HIV DNA in patient samples. Using
this method we can more accurately measure reservoir size in a
wide range of patients, including ES patients, patients on HAART
and others. We find that ES patients harbor a smaller reservoir of
integrated HIV DNA than well-suppressed patients on HAART.
These patients harbor high levels of 2-LTR circular HIV-DNA,
confirming that there is an excess of unintegrated HIV DNA in
this patient population. Our findings add significantly to our
understanding of the mechanisms that allow viral control in this
unique patient population.
Materials and Methods
Integration assay
The two-step repetitive sampling integration assay for patient
samples has been previously described [20]. Briefly, a first step
PCR reaction containing a forward primer specific for the human
Alu element and a reverse primer specific for the HIV gag gene is
followed by a nested, real-time PCR reaction containing primers
and a probe specific for the HIV LTR, allowing for quantification
by cycle threshold values. Samples are analyzed in a minimum of
Table 2. Percentage of integrated HIV DNA per reverse
transcript.
ES CD4+ T cells Normal Donor CD4+ T cells
in vitro 42 31
ES Patients Off HAART On HAART
in vivo (HIV+) 6.6 19.2 39
doi:10.1371/journal.ppat.1001300.t002
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same method using only gag primers to account for background
signals from unintegrated HIV DNA. We require a minimum of 5
positive signals to quantify each sample. Therefore, the number of
repeats assayed varied from patient to patient, but was always
greater than or equal to 42 replicates. Each patient is assayed on
different days and on occasions it is required that we assay one
patient on multiple different days to obtain robust measurements
of integration (i.e. 5 positive wells). Therefore to control for day to
day variation, we run 4 IS control samples on each run and
require that the Ct values for these samples fall within a small
range.
Measurement of total HIV DNA
PCR amplification targeting the RU5 region of HIV was
performed using the same primers and probe used in the second
step of the integration reaction [21] in a single round of 40 cycles.
DNA samples were diluted to contain 1e6, 5e5, and 2.5e5 cells per
well for analysis in triplicate wells of a 96 well plate. Ct values were
inserted into a regression line equation obtained from a standard
curve from the same reaction using samples with known copy
numbers of pNL4-3 plasmids. The mean and standard deviation
of the nine measurements were calculated for each sample.
High DNA concentration standard curve (300,000
genomes per well)
In order to enhance our ability to detect integrated DNA in
patient samples with extremely low levels, the number of genomes
assayed per well was increased from 15,000 genomes (7,500 cell
equivalents) to 300,000 genomes (150,000 cell equivalents) per
reaction. Our previous measurements were performed by diluting
DNA samples to a concentration of 2 mg/mL or 15,000 genomes
in 25 mL (low concentration) and then adding 25 mL of master
mix. We chose a new concentration of 40 mg/mL or 300,000
genomes per 25 mL to establish a new standard curve. The final
volume for each reaction is 50 mL/well, resulting in a final
concentration of 1 mg/mL (low concentration) or 20 mg/mL (high
concentration) of sample DNA.
Analysis of integration level using Ln(Ct) vs Ln(HIV copies
per well)
Using dilutions of our integration standard, previously described
[28], in PBMC DNA and the repetitive sampling method, a
standard curve was generated by plotting the natural log of the
average cycle threshold versus the natural log of the number of
HIV DNA copies per well at 300,000 genomes per well in order to
calculate a new regression equation. The dynamic range of the
high genome assay using this method is from 3.33 to 185
integrated HIV DNA copies per million cells. The top dilution of
the standard was chosen based on the detection limit of our prior
assay. When levels of integration are above this range our standard
integration assay provides robust measurements and is the
preferred method as it requires much less DNA [21].
Analysis of integration level using percent of positive
signals vs HIV copies per well
Standard curves were also generated by plotting the percent
positive versus the integration levels for both the low (15,000
genomes per well) and high (300,000 genomes per well) DNA
concentrations of genomes. The upper limit for the low genome
curve is 133 integrated HIV DNA copies per million cells (or
about 1 provirus per well with 7,500 cells) and the upper limit for
the high genome curve is 16.6 integrated HIV DNA copies per
million cells (or about 2.5 proviruses per well with 15,000 cells).
The upper limit for these standard curves is caused by the plateau
that occurs when 100% of wells are positive. In general, we only
use repetitive sampling when less than 10% of the wells give a
positive signal. The lower limit is defined by the number of
replicate assays that are performed and so theoretically there is no
lower limit. This analysis was used when either the average Ct for
the Alu-gag signal was not significantly different than the gag-only
signal, or when there was a limited amount of sample to assay as
the percent positive method is more sensitive.
Study subjects and ethics statement
Subjects were recruited by Connors and Migueles from the
Clinical Research Center, National Institutes of Health (Bethesda,
MD) and signed informed consent forms were approved by the
National Institute of Allergy and Infectious Diseases Investiga-
tional Review Board. The University of Pennsylvania’s Institu-
tional Review Board approved the transfer and use of materials for
this research. Frozen PBMC from ten elite suppressors (Table 1)
were available for analysis. The patients are part of a cohort
studied at NIH under protocol # 02-I-0086 and provide pheresis
products every 6 to 12 months for research use [5,31]. Each
patient maintained a viral load below the limit of detection (,50
copies per mL) for at least eleven years post-diagnosis (median 22
(range 11–31) years) and all were either HLA-B*57 or B*27
positive. Median CD4 counts were 884 (range 559-1616) cells/ml
and median CD8 counts were 707 (range 300–1118) cells/ml.
PBMC were thawed and genomic DNA was extracted using the
Blood and Cell Culture Maxi Prep Kit (Qiagen, Valencia, CA).
DNA samples were analyzed for total, integrated, and 2-LTR
circular HIV DNA.
We have previously published measurements of total and
integrated HIV DNA in samples from 17 patients on and 6
patients off HAART [21,22]. We have since measured total and
integrated HIV DNA in two more patients off and four more
patients on HAART (from NIH, Table S3). We used these
measurements for comparisons with our new ES patient samples.
The patients referred to as being off HAART had never been
treated with antiretroviral therapies (treatment naı ¨ve). The 2-LTR
circular HIV DNA for this study had not been previously
published.
Assay for circular 2-LTR HIV DNA
HIV 2-LTR segments were amplified using a kinetic PCR assay
and methods previously described [64]. Serial dilutions of the 2-
LTR plasmid of 1:3 were preformed in a background of
uninfected PBMC DNA. The dilutions were assayed from 1000
copies/well down to 1.4 copies/well. Using this method a positive
signal from wells containing 1.4 copies could be detected 77% of
the time, consistent with what would be predicted by the Poisson
distribution. Samples containing 1.4 copies had the largest
coefficient of variation (1.29).
In vitro infection of CD4+ enriched PBMC from ES and
HIV- donors
PBMC from all ten ES were stained with FITC labeled lineage
markers for CD8, CD14, CD16, CD20, CD56, CD11c. CD4
+ T
cells were negatively selected following the anti-FITC bead
depletion protocol (Miltenyi Biotec, Germany). CD4
+ T cells were
spinoculated with pNL4-3 virus at a high MOI (such that there
was on average 1–2 reverse transcripts per cell). In addition,
samples from 6 of the 10 ES individuals were spinoculated with 3
serial ten-fold dilutions of virus. Cells from HIV-negative donors,
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spinoculation, cells were treated with saquinavir to inhibit
spreading infection. At two and four days post-infection, DNA
was isolated with the DNA micro kit (Qiagen, Valenica, Ca).
Reverse transcription was measured using the same primers used
for patient samples, targeting the RU5 region, and integration was
measured by our in vitro integration assay (as described in [65]).
The nonparametric Wilcoxon rank-sum test was used to compare
measurements of reverse transcription and integration in the ES
samples to those from the HIV-negative donor samples. A p-value
of ,0.05 would have been considered significant.
Statistical analyses
The nonparametric Wilcoxon rank-sum test was used for
unpaired comparisons. The associations between variables were
assessed using the Spearman’s rank correlation test or simple
linear regression analysis. Chi-square test was used to assess
whether differences in the percentage of LTR positive samples
among groups were statistically significant. P values ,0.05 were
considered to be statistically significant. Statistical analyses were
performed using WinSTAT.
Supporting Information
Figure S1 Generation of standard curves using percent positive
quantitation. At very low levels of integrated HIV DNA, the
average signal from the integration-positive wells overlaps with the
average signal from the control wells. In other words, the
difference between the Ct values is no longer statistically
significant (t-test p$0.05). Consequently, we used a new method
of quantitation that distinguishes the positive signals from
background and uses the percent of positive signals to determine
the number of integrated HIV DNA copies in a sample of cells.
Dilutions of our polyclonal integration standard were used to
define the correlation between the percent of wells with positive
signals and the number of copies of integrated HIV DNA per well.
The standard, which has one copy of integrated HIV DNA per
cell distributed randomly to mimic a patient infection, was tested
at 8 different dilutions from five copies per well down to 0.1 copies
per well using the repetitive sampling method. Each dilution was
made with 2 and 40 mg/mL PBMC DNA (final concentrations 1
and 20 mg/mL), isolated from HIV-negative donors, to yield a
range of integration levels. The percent of positive wells was then
plotted against the number of copies of integrated HIV DNA per
well to calculate a regression equation. Error for this assay is
calculated by the quotient formula (p(1-p)) for the Poisson
distribution. A The integration standard was diluted in PBMC
DNA and assayed for Alu-gag and gag-only using repetitive
sampling PCR as described at high, intermediate and low number
of integration events per well. The top paired panels are the typical
PCR curves generated when there are high levels of integrated
HIV DNA in a patient sample, the average Ct value of Alu-gag
signals is always lower than that of gag-only signals and there is less
variability between Ct values for individual wells. The middle
panel shows the PCR curves generate at intermediate levels of
integrated HIV DNA. Here, there is greater variability between
individual Ct values due to the array of distances between Alu and
gag in any given sample and some of the signals overlap with gag-
only controls. However the average Alu-gag is still significantly
lower than the gag-only. Finally, the bottom panel shows the PCR
curves when there are low levels of integrated HIV DNA. In this
case, the average Alu-gag and average gag only are not statistically
different. Nonetheless, positive signals are still detected outside of
the gag-only range. In this final situation, we must use the percent
positive method to detect integration as described below. B,C
There is a linear correlation between the percent of positive signals
and the number of integrated HIV DNA copies per well at both 1
(low DNA concentration, B) and 20 (high DNA concentration, C)
mg/mL of DNA. The standard curve was generated by diluting IS
in a constant number of uninfected cells. PCR was performed on
multiple replicates at each concentration. The percentage of
positive wells at any dilution was determined and plotted against
the known number of integration events. To determine the
number of positive wells, the average Ct +/- two standard
deviations from the gag-only signal are applied to the Alu-gag signals
to determine if the difference between Alu-gag and gag-only signals
is significant (p,0.05).
Found at: doi:10.1371/journal.ppat.1001300.s001 (1.33 MB TIF)
Figure S2 Integrated and Total HIV DNA measurements
normalized to CD4+T cell count and uL of blood. For 11 of the
patients on HAART and all 10 of the ES patients tested, we were
able to normalize the measurements of integrated HIV DNA and
total HIV DNA to copies per million CD4+T cells (A,B) and
copies per uL of blood (C,D). The level of integrated HIV DNA
was still significantly lower in ES compared to patients on
HAART (A,C) and total HIV DNA was still not statistically
different between the two groups (B, D) by either method of
normalization. The lines represent the median values.
Found at: doi:10.1371/journal.ppat.1001300.s002 (0.15 MB TIF)
Table S1 Validation of quantitation methods: Both assays
provide similar integration levels when tested in patient samples.
Five patient samples were measured at both (low and high) DNA
concentrations, and the average levels of integrated HIV DNA
measured are shown. At these concentrations, the samples
required quantitation by the percent positive method at the low
DNA concentration and the average Ct method at the high DNA
concentration. D and E were measured in triplicate, while A, B
and C were single measurements due to limiting sample. When
compared at the two concentrations, the measurements for D and
E were similar.
Found at: doi:10.1371/journal.ppat.1001300.s003 (0.03 MB
DOC)
Table S2 Reproducibility of total and integrated HIV DNA
assays. The same patient sample was assayed for total and
integrated HIV DNA separately, a total of 6 times. Each assay was
performed by a different person twice, so that 3 people
independently measured the sample for each intermediate.
Found at: doi:10.1371/journal.ppat.1001300.s004 (0.03 MB
DOC)
Table S3 Characteristics of additional patients on and off
HAART.
Found at: doi:10.1371/journal.ppat.1001300.s005 (0.03 MB
DOC)
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